Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 10/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4562961 | 0.97 | PARP1 (0.50) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL2431512 | 0.91 | TSHR (0.52) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL30471810 | 0.88 | BCAT2 (0.52) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL160022 | 0.88 | ESR1 (0.49) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL30933674 | 0.88 | ESR1 (0.49) | KDM4EALDH1A1MAPTHPGDTSHR | |
| 1,2-Dichlorobenzene SCHEMBL27708578 | 0.87 | KDM4E (0.59) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL29778068 | 0.86 | KDM4E (0.61) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL1804941 | 0.86 | KDM4E (0.61) | KDM4EALDH1A1MAPTHPGDTSHR | |
| Hydrochloric Acid SCHEMBL27700838 | 0.86 | ESR1 (0.47) | KDM4EALDH1A1MAPTHPGDTSHR | |
| Iodide SCHEMBL27448066 | 0.86 | ESR1 (0.47) | KDM4EALDH1A1MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028419-A | A kind of preparation method of Iopromide | 台州学院 | 2019-07-19 | — | — | CN | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| CN-115960010-A | Preparation of aniline compounds | 上海慧聚药业有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115160172-A | Preparation process of iopromide | 江苏宇田医药有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-111410615-A | Preparation method and application of iopromide intermediate | 正大天晴药业集团股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-110028419-A | A kind of preparation method of Iopromide | 台州学院 | 2019-07-19 | — | — | CN | disclosed |
| CN-110015972-A | A kind of preparation method of Iopromide intermediate | 台州学院 | 2019-07-16 | — | — | CN | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| CN-106456627-A | Methods for treating cancer and preventing cancer drug resistance | 基因泰克公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | ASTERAND, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1339702-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2001068619-A1 | 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEX INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| US-5686645-A | REACTION WITH ALCOHOL TO FORM CARBAMATE, TRANSITION METAL CATALYST | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5155267-A | Forming unsymmetric carbamates and ureas; reacting primary formamide with dialkyl amine or alcohol | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 1992-10-13 | — | — | US | disclosed |
| US-4147725-A | Process for preparing aniline compounds from amides with rhodium | THE DOW CHEMICAL COMPANY (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 113/4885ALDH1A1 2987/4885MAPT 3623/4885 |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM4E 118/4885ALDH1A1 2910/4885MAPT 3678/4885 |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | PTGER3, PTGER1, PTGER4 | KDM4E 4399/4885ALDH1A1 1588/4885MAPT 4800/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | KDM4E 242/4885ALDH1A1 589/4885MAPT 43/4885 |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | KDM4E 3054/4885ALDH1A1 2178/4885MAPT 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.